Summit Therapeutics Inc.
SMMT
Clasificación en acciones
#1702
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Precio por acción
$15.71
Última sincronización: 2026-10-19
Capitalización bursátil
$12.53B
Cambio (1 día)
7.35%
Cambio (1 año)
-21.63%
País
US
Comercio Summit Therapeutics Inc. (SMMT)
Categoría
Healthcare
EPS de Summit Therapeutics Inc. (SMMT)
EPS a fecha de June 2026 TTM: $-1.12
Según los últimos informes financieros y el precio de las acciones de Summit Therapeutics Inc., el EPS actual de la empresa (TTM) es $-1.12. Al final del año 2023, la empresa tenía un EPS de $-0.99 un aumento con respecto a al EPS de 2022, que fue de $-0.41.
Historial de EPS de Summit Therapeutics Inc. desde 2004 hasta 2026
EPS al final de cada año
| Año | EPS | Cambiar |
|---|---|---|
| 2026 (TTM) | $-1.12 | 261.29% |
| 2024 | $-0.31 | -68.69% |
| 2023 | $-0.99 | 141.46% |
| 2022 | $-0.41 | -57.29% |
| 2021 | $-0.96 | 26.32% |
| 2020 | $-0.76 | 282.10% |
| 2019 | $-0.20 | -12.46% |
| 2018 | $-0.23 | -58.03% |
| 2017 | $-0.54 | -7.28% |
| 2016 | $-0.58 | -9.84% |
| 2015 | $-0.65 | 15.87% |
| 2014 | $-0.56 | -16.06% |
| 2013 | $-0.67 | 17.30% |
| 2012 | $-0.57 | 86.96% |
| 2011 | $-0.30 | 45.47% |
| 2010 | $-0.21 | -75.78% |
| 2009 | $-0.86 | 3.18% |
| 2008 | $-0.84 | 166.41% |
| 2007 | $-0.31 | 191.63% |
| 2006 | $-0.11 | 1,435.71% |
| 2005 | $-0.01 | 75.00% |
| 2004 | 0.00 | 0.00% |
EPS de empresas similares o competidoras
| Empresa | EPS | Diferencia de EPS | País |
|---|---|---|---|
| $17.32 | -1,646.43% |
US
|
|
| $-7.98 | 612.50% |
US
|
|
| $-5.29 | 372.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,576.79% |
NL
|
